1246834-64-9 Usage
General Description
Pyrimidin-2-ylmethanamine acetate is a chemical compound that consists of a pyrimidine ring with a methanamine group attached at the 2-position, along with an acetate group. The pyrimidine ring is a six-membered heterocyclic ring that contains two nitrogen atoms and four carbon atoms. The methanamine group is a primary amine, which means that it has a nitrogen atom bonded to two hydrogen atoms and one carbon atom. The acetate group is a functional group that contains a carbonyl group and an alkoxy group, which makes it a derivative of acetic acid. Pyrimidin-2-ylmethanamine acetate may have various applications in the field of organic synthesis and medicinal chemistry due to its unique structural features.
Check Digit Verification of cas no
The CAS Registry Mumber 1246834-64-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,4,6,8,3 and 4 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1246834-64:
(9*1)+(8*2)+(7*4)+(6*6)+(5*8)+(4*3)+(3*4)+(2*6)+(1*4)=169
169 % 10 = 9
So 1246834-64-9 is a valid CAS Registry Number.
1246834-64-9Relevant articles and documents
NOVEL PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER
-
, (2012/04/17)
The present invention is to provide a therapeutic agent for attention deficit/hyperactivity disorder having a novel mechanism of action which is different from conventional psychostimulants. The present invention is useful for providing an excellent pharmaceutical composition for prevention and/or treatment of attention deficit/hyperactivity disorder, comprising a BEC1 potassium channel inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, and is particularly useful for providing a pharmaceutical composition for prevention and/or treatment of inattention, impulsivity, and hyperactivity in attention deficit/hyperactivity disorder.
